- ISIN
- US87990A1060
- CUSIP
- 87990A106
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jul 30, 2021
Highlights
- Market Cap
- $151.82M
- Enterprise Value
- $84.16M
- EPS (TTM)
- -$0.48
- Total Revenue (TTM)
- $225.00K
- EBITDA (TTM)
- -$78.62M
- Year Range
- $0.53 - $2.35
- Target Price
- $2.33
- ROA (TTM)
- -61.45%
- ROE (TTM)
- -78.17%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
TNYA Performance Chart
Tenaya Therapeutics, Inc. (TNYA) is down 1.6% since the beginning of the year. At $1 per share, TNYA is trading 70.2% below its 52-week high of $2.
Loading charts...
Returns By Period
Tenaya Therapeutics, Inc. (TNYA) has returned -1.62% so far this year and 19.23% over the past 12 months.
Tenaya Therapeutics, Inc.
- 1D
- -4.19%
- 1M
- -9.39%
- YTD
- -1.62%
- 6M
- -7.54%
- 1Y
- 19.23%
- 3Y*
- -50.41%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
TNYA Monthly Returns History
Based on dividend-adjusted daily data since Jul 30, 2021, TNYA's average daily return is -0.02%, while the average monthly return is -0.75%.
Historically, 33% of months were positive and 67% were negative. The best month was Apr 2023 with a return of +86.5%, while the worst month was Dec 2024 at -59.9%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 9 months.
On a daily basis, TNYA closed higher 45% of trading days. The best single day was Mar 5, 2026 with a return of +40.9%, while the worst single day was Mar 4, 2025 at -53.5%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 8.88% | -27.48% | 23.25% | -0.19% | 25.74% | -19.45% | -1.62% | ||||||
| 2025 | -25.87% | -4.72% | -43.55% | -16.68% | -3.16% | 32.87% | 10.60% | 67.16% | 43.36% | -11.11% | -2.78% | -49.18% | -50.24% |
| 2024 | 29.78% | 41.50% | -12.10% | -13.19% | -7.27% | -26.37% | 12.90% | -23.43% | -27.99% | -0.52% | 85.94% | -59.94% | -55.86% |
| 2023 | 70.15% | -10.23% | -7.17% | 86.49% | 35.47% | -18.47% | -17.55% | -20.04% | -34.11% | -28.63% | 3.30% | 72.34% | 61.19% |
| 2022 | -37.10% | -2.18% | 1.03% | -21.73% | -27.33% | -15.97% | -15.28% | -7.97% | -33.94% | -7.59% | -1.12% | -24.15% | -89.39% |
| 2021 | -21.28% | 31.92% | 1.98% | 24.50% | -23.57% | -3.56% | -2.82% |
Benchmark Metrics
Tenaya Therapeutics, Inc. has an annualized alpha of -25.68%, beta of 1.92, and R2 of 0.09 versus S&P 500 Index. Calculated based on daily prices since July 30, 2021.
- This stock participated in 267.38% of S&P 500 Index downside but only 257.29% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.09 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -25.68%
- Beta
- 1.92
- R²
- 0.09
- Upside Capture
- 257.29%
- Downside Capture
- 267.38%
Return for Risk
Risk / Return Rank
TNYA ranks 52 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Tenaya Therapeutics, Inc. (TNYA) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| TNYA | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.86 | ||
| Sortino ratioReturn per unit of downside risk | -1.61 | ||
| Omega ratioGain probability vs. loss probability | 1.14 | 1.37 | -0.23 |
| Calmar ratioReturn relative to maximum drawdown | 0.26 | 2.78 | -2.52 |
| Martin ratioReturn relative to average drawdown | 0.40 | 12.44 | -12.04 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Tenaya Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Tenaya Therapeutics, Inc. was 98.69%, occurring on May 14, 2025. The portfolio has not yet recovered.
The current Tenaya Therapeutics, Inc. drawdown is 97.63%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -98.69%May 2025 | 3y 6mo | — | 4y 7moNov 2021 - now |
2021 bear market2021 | -31.70%Sep 2021 | 23d | 1mo 14d | 2mo 7dAug 2021 - Nov 2021 |
2021 bear market2021 | -21.28%Jul 2021 | 0s | 10d | 10dJul 2021 - Aug 2021 |
2021 pullback2021 | -8.00%Aug 2021 | 3d | 4d | 7dAug 2021 - Aug 2021 |
2021 pullback2021 | -6.64%Aug 2021 | 0s | 2d | 2dAug 2021 - Aug 2021 |
Drawdown Indicators
| TNYA | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.69% | -56.78% | -41.91% |
Max Drawdown (1Y)Largest decline over 1 year | -73.81% | -9.10% | -64.71% |
Max Drawdown (3Y)Largest decline over 3 years | -94.30% | -18.90% | -75.40% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -97.63% | -1.80% | -95.83% |
Average DrawdownAverage peak-to-trough decline | -82.21% | -10.71% | -71.50% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 48.53% | 2.03% | +46.50% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Tenaya Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Tenaya Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for TNYA relative to other companies in the Biotechnology industry. Currently, TNYA has a P/S ratio of 541.3. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for TNYA in comparison with other companies in the Biotechnology industry. Currently, TNYA has a P/B value of 1.4. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with TNYA
Add Tenaya Therapeutics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with TNYA